BioXcel Therapeutics (BTAI)
(Delayed Data from NSDQ)
$1.81 USD
+0.03 (1.69%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.75 -0.06 (-3.31%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
BioXcel Therapeutics, Inc. [BTAI]
Reports for Purchase
Showing records 101 - 109 ( 109 total )
Company: BioXcel Therapeutics, Inc.
Industry: Unclassified
2Q18 Financial Results Reported; Significantly Lower-Than-Projected Spending; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Unclassified
Business Development Head Appointed; Clinical Trial Milestones Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Unclassified
BXCL701 Principal Mechanism Highlighted in Peer-Reviewed Publication; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Unclassified
Neuroscience Clinical Advisory Board Formed; Further Milestones Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Unclassified
Positive Phase 1b IV Dexmedetomidine Study Data to Support BXCL501 Development; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Unclassified
Chief Medical Officer Formally Appointed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Unclassified
BXCL701 ASCO Poster Presentation Provides Hints of Intriguing Combo Activity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Unclassified
1Q 2018 Results Reported; Solid Cash Position; ASCO Catalyst Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: BioXcel Therapeutics, Inc.
Industry: Unclassified
Supercharging Drug Development via Artificial Intelligence; Initiating at Buy and $25 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R